Mary Macri

455 total citations
20 papers, 225 citations indexed

About

Mary Macri is a scholar working on Oncology, Genetics and Biotechnology. According to data from OpenAlex, Mary Macri has authored 20 papers receiving a total of 225 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 6 papers in Genetics and 6 papers in Biotechnology. Recurrent topics in Mary Macri's work include Cancer Immunotherapy and Biomarkers (13 papers), Cancer Research and Treatments (6 papers) and Immunotherapy and Immune Responses (5 papers). Mary Macri is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Cancer Research and Treatments (6 papers) and Immunotherapy and Immune Responses (5 papers). Mary Macri collaborates with scholars based in United States, Australia and Switzerland. Mary Macri's co-authors include Toni Ricciardi, Aileen Ryan, Ralph Venhaus, Paul Schwarzenberger, Gavin P. Dunn, David A. Reardon, Jörg Dietrich, Hui Gan, Andrew J. Park and Timothy F. Cloughesy and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Gynecologic Oncology.

In The Last Decade

Mary Macri

20 papers receiving 221 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mary Macri United States 9 169 105 96 48 43 20 225
Toni Ricciardi United States 9 173 1.0× 106 1.0× 96 1.0× 50 1.0× 45 1.0× 25 233
Aileen Ryan United States 9 173 1.0× 106 1.0× 96 1.0× 50 1.0× 45 1.0× 21 230
Sanne H. Hendriks Netherlands 5 156 0.9× 112 1.1× 25 0.3× 30 0.6× 51 1.2× 7 266
Yumiko Higuchi Japan 10 167 1.0× 166 1.6× 54 0.6× 48 1.0× 92 2.1× 30 305
Carolyn G. Chapman United States 6 131 0.8× 87 0.8× 36 0.4× 96 2.0× 51 1.2× 7 217
Laura Deedigan Ireland 7 85 0.5× 54 0.5× 121 1.3× 38 0.8× 172 4.0× 8 291
Megan Wachsmann United States 7 167 1.0× 73 0.7× 9 0.1× 16 0.3× 79 1.8× 11 273
Fransien de Boer Netherlands 7 92 0.5× 115 1.1× 130 1.4× 17 0.4× 89 2.1× 14 324
Joanna Kelly United Kingdom 7 43 0.3× 33 0.3× 100 1.0× 33 0.7× 108 2.5× 9 230
Jessica Waibl Polania United States 7 178 1.1× 202 1.9× 32 0.3× 23 0.5× 85 2.0× 12 331

Countries citing papers authored by Mary Macri

Since Specialization
Citations

This map shows the geographic impact of Mary Macri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Macri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Macri more than expected).

Fields of papers citing papers by Mary Macri

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Macri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Macri. The network helps show where Mary Macri may publish in the future.

Co-authorship network of co-authors of Mary Macri

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Macri. A scholar is included among the top collaborators of Mary Macri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Macri. Mary Macri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Middleton, Mark R., Ioannis Karydis, Xin Lü, et al.. (2023). Long-term outcomes from adding durvalumab to neoadjuvant treatment of operable gastroesophageal cancers: Results from a multicenter study LUD2015-005.. Journal of Clinical Oncology. 41(4_suppl). 398–398. 2 indexed citations
2.
Zamarin, Dmitriy, Kunle Odunsi, Emese Zsíros, et al.. (2022). Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic durvalumab in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Phase 2 results.. Journal of Clinical Oncology. 40(16_suppl). 2600–2600. 5 indexed citations
3.
Slingluff, Craig L., Ileana S. Mauldin, Elizabeth Gaughan, et al.. (2021). 337 Intratumoral immune therapy for recurrent breast cancer with polyICLC, and tremelimumab combined with systemic durvalumab. Regular and Young Investigator Award Abstracts. A363–A363. 2 indexed citations
4.
Slingluff, Craig L., Hassane M. Zarour, Hussein A. Tawbi, et al.. (2021). A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. OncoImmunology. 10(1). 1898105–1898105. 20 indexed citations
5.
6.
7.
Reardon, David A., Thomas Kaley, Jörg Dietrich, et al.. (2019). Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).. Journal of Clinical Oncology. 37(15_suppl). 2032–2032. 43 indexed citations
8.
Sabari, Joshua K., Paul Schwarzenberger, Toni Ricciardi, et al.. (2019). Abstract B209: Phase 1/2 study of mRNA vaccine therapy + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC). Cancer Immunology Research. 7(2_Supplement). B209–B209. 12 indexed citations
9.
Callahan, Margaret K., Kunle Odunsi, Mario Sznol, et al.. (2019). Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors. Cancer Immunology Research. 7(2_Supplement). A006–A006. 1 indexed citations
10.
Zamarin, Dmitriy, Kunle Odunsi, Brian M. Slomovitz, et al.. (2019). Abstract A022: Phase 1/2 study to evaluate systemic durvalumab (durva) + intraperitoneal ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC). Cancer Immunology Research. 7(2_Supplement). A022–A022. 1 indexed citations
11.
Gandhi, Leena, Paul Schwarzenberger, Toni Ricciardi, et al.. (2018). Phase 1/2 study of mRNA vaccine therapy + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 36(15_suppl). TPS9107–TPS9107. 13 indexed citations
12.
O’Cearbhaill, Roisin E., Anita Wolfer, Paul DiSilvestro, et al.. (2018). A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC). Annals of Oncology. 29. viii337–viii337. 14 indexed citations
13.
Reardon, David A., Thomas Kaley, Jörg Dietrich, et al.. (2018). ATIM-38. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) + BEVACIZUMAB (BEV) IN BEV-NAÏVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology. 20(suppl_6). vi10–vi10. 7 indexed citations
14.
Callahan, Margaret K., Kunle Odunsi, Mario Sznol, et al.. (2017). Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, DUR) + tremelimumab (TRE) in patients with advanced solid tumors.. Journal of Clinical Oncology. 35(15_suppl). 3069–3069. 23 indexed citations
15.
Reardon, David A., Thomas Kaley, Jörg Dietrich, et al.. (2017). Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: An update.. Journal of Clinical Oncology. 35(15_suppl). 2042–2042. 41 indexed citations
16.
Slingluff, Craig L., Paul Schwarzenberger, Toni Ricciardi, et al.. (2017). Phase 1/2 study of in situ vaccination with tremelimumab + intravenous (IV) durvalumab + poly-ICLC in patients with select relapsed, advanced cancers with measurable, biopsy-accessible tumors.. Journal of Clinical Oncology. 35(15_suppl). TPS3106–TPS3106. 4 indexed citations
17.
Reardon, David A., Thomas Kaley, Jörg Dietrich, et al.. (2017). ATIM-12. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH BEVACIZUMAB (BEV)-REFRACTORY RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology. 19(suppl_6). vi28–vi28. 8 indexed citations
18.
19.
20.
Reardon, David A., Thomas Kaley, Jörg Dietrich, et al.. (2016). Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM).. Journal of Clinical Oncology. 34(15_suppl). TPS2080–TPS2080. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Toni Ricciardi Breakdown of academic impact, for papers by Aileen Ryan Breakdown of academic impact, for papers by Sanne H. Hendriks Breakdown of academic impact, for papers by Yumiko Higuchi Breakdown of academic impact, for papers by Carolyn G. Chapman Breakdown of academic impact, for papers by Laura Deedigan Breakdown of academic impact, for papers by Megan Wachsmann Breakdown of academic impact, for papers by Fransien de Boer Breakdown of academic impact, for papers by Joanna Kelly Breakdown of academic impact, for papers by Jessica Waibl Polania
Rankless by CCL
2026